Arrowstreet Capital
AUPH icon

Arrowstreet Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Arrowstreet Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.4M Sell
3,264,062
-20,306
-0.6% -$324K 0.02% 521
2026
Q1 		$48.7M Sell
3,284,368
-102,826
-3% -$1.5M 0.03% 497
2025
Q4 		$54M Buy
3,387,194
+13,173
+0.4% +$187K 0.03% 464
2025
Q3 		$37.3M Buy
3,374,021
+2,297,903
+214% +$25.1M 0.02% 544
2025
Q2 		$9.11M Sell
1,076,118
-564,314
-34% -$4.52M 0.01% 935
2025
Q1 		$13.2M Buy
1,640,432
+564,521
+52% +$4.57M 0.01% 730
2024
Q4 		$9.66M Buy
+1,075,911
New +$8.78M 0.01% 839

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arrowstreet Capital's AUPH Position: Q2 2026 in Review

Arrowstreet Capital reduced its Aurinia Pharmaceuticals (AUPH) stake by 0.62% in Q2 2026, selling an estimated $324K and leaving 3,264,062 shares worth $55.4M. The position accounts for 0.02% of the portfolio, ranked #521.

Arrowstreet Capital first reported a position in AUPH in Q4 2024 and has held it in 7 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Arrowstreet Capital held 3,264,062 shares of Aurinia Pharmaceuticals worth $55.4M as of Q2 2026.
  • Arrowstreet Capital sold 20,306 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $324K.
  • Aurinia Pharmaceuticals made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #521 holding.
  • Arrowstreet Capital first reported a position in Aurinia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.